Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05600634
Other study ID # 2023-0719
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 1, 2024
Est. completion date December 31, 2026

Study information

Verified date October 2023
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact Chenggang Yi, M.D.
Phone +8613567113534
Email cwar@163.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study was to explore the accuracy of sentinel skin grafts from the same donor source in diagnosing renal allograft rejection, and to provide new ideas and options for the later clinical diagnosis of renal allograft rejection. Further, try to provide timing guidance for early immunization intervention.


Recruitment information / eligibility

Status Recruiting
Enrollment 24
Est. completion date December 31, 2026
Est. primary completion date June 30, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: 1. Patients with end-stage renal disease undergoing renal transplantation; 2. 18-60 years old; 3. Postoperative follow-up points are complete (visit the hospital every week in the first month after surgery, every two weeks in 2-3 months, every four to six months, and every three months in 7-12 months. Follow up at any time when skin rejection is observed. The follow-up time may be adjusted when the condition changes); 4. The participants had good compliance, volunteered to participate in the test and signed the informed consent form. Exclusion Criteria: 1. Untreated or disseminated malignant tumor; 2. Active period of infectious diseases; 3. Serious cardiovascular disease occurred recently; 4. Combined with other important organ failure; 5. History of mental illness or cognitive impairment;

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Skin allotransplantation
Sentinel skin grafts from the same donor source will be carried on in the meantime of kidney transplantation for assisting to detect acute renal rejection.

Locations

Country Name City State
China First Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou Zhejiang
China Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University Hangzhou Zhejiang
China Xijing Hospital, Ari Force Medical University Xi'an Shannxi

Sponsors (4)

Lead Sponsor Collaborator
Second Affiliated Hospital, School of Medicine, Zhejiang University Sir Run Run Shaw Hospital, Xijing Hospital, Air Force Medical University, Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary 2017 Banff Kidney Transplantation Rejection Rating A rating evaluation on kidney rejection Through study completion, an average of 1 year
Primary 2007-edition Banff skin containing allogeneic composite histopathological diagnosis grading Skin histopathological diagnosis Through study completion, an average of 1 year
Primary Renal function testing Blood Cr and Bun testing Through study completion, an average of 1 year
Secondary Renal ultrasound diagnosis Renal ultrasound diagnosis Through study completion, an average of 1 year
Secondary Complications Complications assessment Through study completion, an average of 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT04491552 - TruGraf® Long-term Clinical Outcomes Study
Withdrawn NCT04560582 - Immunosuppression Reduction in Failed Allograft Guided by cfDNA
Completed NCT05747274 - SRDK0921_ Analytical Performance Study
Not yet recruiting NCT05482100 - CLinical Utility of the omnigrAf® biomarkeR Panel In The Care of kidneY Transplant Recipients
Recruiting NCT06243289 - Improving KIdney Transplantation With Cellular Therapy Study
Not yet recruiting NCT06025240 - Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
Completed NCT04367610 - Effects of A Standardized Treatment Approach on Kidney Transplant Recipients With Antibody-Mediated Rejection
Enrolling by invitation NCT06126380 - Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients Phase 2
Terminated NCT05747053 - Personalization of Immunosuppressive Treatment for Organ Transplant Recipients
Active, not recruiting NCT03714113 - Donor-specific Anti-HLA Antibodies Monitoring in Kidney Transplant Recipients N/A
Recruiting NCT04091984 - The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)
Recruiting NCT05335538 - TruGraf and TRAC In Pediatrics Study
Completed NCT03663335 - Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients Phase 2
Completed NCT03652402 - Precision Risk Stratification in Kidney Transplant Patients - EU-TRAIN
Recruiting NCT04773392 - Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR Phase 4
Completed NCT03873623 - The TOGETHER Project - Kidney
Terminated NCT02974686 - Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation Phase 4
Terminated NCT04156204 - Immunosuppressant Medication Dosed Daily After Kidney Transplant Early Phase 1
Completed NCT04601155 - Transition of Renal Patients Using AlloSure Into Community Kidney Care
Completed NCT03874299 - The TOGETHER Project - Kidney RNA-seq Validation